Genzyme Corporation News & Latest Genzyme Corporation Headlines

Is Celgene the Perfect Stock?

2:00PM 4/06/2011

Company News, Technology, Economy, Investing, Health Care, Genzyme Corporation , Pfizer, Merck, Market News, Investment

With an attractive balance sheet, healthy revenue growth and a solid return on equity, biotech company Celgene looks like a promising stock buy.

Sanofi to Buy Genzyme in $20.1 Billion Deal

6:30AM 2/16/2011

By Douglas McIntyre

Company News, Earnings, Genzyme Corporation , Sanofi Aventis

French drug company Sanofi-Aventis (SNY) has finally made a deal to buy biotech company Genzyme (GENZ) for $20.1 billion, about $74 a share. Genzyme shareholders will get a contingent value right that represents potential future payments if Lemtrada, the company's multiple sclerosis drug, is a...

Still No Deal Between Sanofi-Aventis and Genzyme

12:45PM 2/11/2011

By Melly Alazraki

Health Care, Genzyme Corporation , Sanofi Aventis

What is preventing the French pharmaceutical group and U.S. biotech from reaching a merger agreement?

The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up

8:00PM 2/09/2011

By Melly Alazraki

Health Care, Genzyme Corporation , GlaxoSmithKline, Novartis, Amgen, Eli Lilly

To get potentially lifesaving drugs to patients faster, the U.S. Food and Drug Administration is allowed to approve some drugs -- those that address unmet medical needs -- based on fewer trials than usual. But it turns out that many of the pharmaceutical companies fail to conduct follow-up trials to prove the drugs work.

Sanofi-Aventis, Genzyme Are on the Brink of a Merger

10:40AM 2/07/2011

By Melly Alazraki

Company News, Health Care, Genzyme Corporation , Sanofi Aventis, Stocks in the News

It seems that months of merger talks between French pharma Sanofi-Aventis and U.S. biotech Genzyme have entered the home stretch. This week, Sanofi is expected to offer $74 a share for Genzyme, with an option included potentially worth $5 to $6 a share.

Just How Much Is Sanofi Aventis Offering for Genzyme?

4:10PM 2/02/2011

By Melly Alazraki

Company News, Investing, Health Care, Genzyme Corporation , Sanofi Aventis, Stocks in the News

Just after Genzyme announced that it signed a confidentiality agreement with Sanofi Aventis to allow the French drugmaker to examine its books, leaks about the potential deal started pouring out. The numbers and details vary, so this long battle may not be over yet.

Another Cancer-Drug Failure Highlights Difficulties Facing Pharmas

12:30PM 1/28/2011

By Melly Alazraki

Company News, Columns, Health Care, Genzyme Corporation , Pfizer, Bristol-Myers Squibb, Sanofi Aventis, Novartis, Eli Lilly, Astrazeneca

Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the patent cliff, when they will be forced to compete with cheaper generics.

The Top 10 Health Care Stories of 2010

7:30AM 12/29/2010

By Melly Alazraki

Health Care, Genzyme Corporation , Johnson & Johnson, Pfizer, Sanofi Aventis, Merck, GlaxoSmithKline, Novartis, Abbott, Astrazeneca

Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting -- if not always positive -- year. Here's our rundown of the biggest health care stories.

Genzyme Tries to Convince Sanofi-Aventis Its MS Drug Is Worth More

10:50AM 12/20/2010

By Melly Alazraki

Company News, Genzyme Corporation , Sanofi Aventis, Stocks in the News

The U.S. biotech is holding an analyst and investor meeting focused on the commercial potential of its multiple sclerosis drug Campath. The goal: to convince Paris-based Sanofi-Aventis to raise its hostile takeover offer in a battle that has now gone on for five months.

Sanofi-Aventis Extends Its Tender Offer for Genzyme

9:50AM 12/13/2010

By Melly Alazraki

Company News, Investing, Health Care, Genzyme Corporation , Sanofi Aventis, Stocks in the News

Paris-based pharma Sanofi-Aventis has pushed back its offer deadline for Massachusetts-based biotech Genzyme by six weeks. All other terms, including the $69 per share bid, remain unchanged. So far, very few shareholders have responded.